Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer

被引：7

作者：

Liu, Catherine ^{[1
,2
,3
,8
]}

Yoke, Leah H. ^{[1
,2
]}

Bhattacharyya, Pooja ^{[1
,2
]}

Cassaday, Ryan D. ^{[3
,4
]}

Cheng, Guang-Shing ^{[3
,5
]}

Escobar, Zahra Kassamali ^{[1
,6
]}

Ghiuzeli, Cristina ^{[3
,4
]}

McCulloch, Denise J. ^{[1
,2
,3
]}

Pergam, Steven A. ^{[1
,2
,3
]}

Roychoudhury, Pavitra ^{[1
,7
]}

Tverdek, Frank ^{[1
]}

Schiffer, Joshua T. ^{[1
,2
,3
]}

Ford, Emily S. ^{[1
,2
]}

机构：

[1] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[2] Univ Washington, Div Allergy & Infect Dis, Seattle, WA USA

[3] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA

[4] Univ Washington, Div Hematol, Seattle, WA USA

[5] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA USA

[6] Univ Washington, Sch Pharm, Seattle, WA USA

[7] Univ Washington, Dept Lab Med, Seattle, WA USA

[8] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, 1100 Fairview Ave N, Seattle, WA 98109 USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

基金：

美国国家卫生研究院;

关键词：

extended nirmatrelvir-ritonavir; hematologic cancer; persistent COVID-19;

D O I：

10.1093/ofid/ofad306

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir. Persistent COVID-19 infection is a challenging management dilemma among immunosuppressed individuals, particularly those with B-cell dysfunction. We describe 2 patients with symptomatic COVID-19 for almost 6 months who were successfully treated in the ambulatory setting with extended courses of nirmatrelvir/ritonavir.

引用

页数：4

共 10 条

[1] Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)
Boucau, Julie
Uddin, Rockib
Marino, Caitlin
Regan, James
Flynn, James P.
Choudhary, Manish C.
Chen, Geoffrey
Stuckwisch, Ashley M.
Mathews, Josh
Liew, May Y.
Singh, Arshdeep
Reynolds, Zahra
Iyer, Surabhi L.
Chamberlin, Grace C.
Vyas, Tammy D.
Vyas, Jatin M.
Turbett, Sarah E.
Li, Jonathan Z.
Lemieux, Jacob E.
Barczak, Amy K.
Siedner, Mark J.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E526 - E529
[2] Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19)
Chan, Gordon Chun Kau
Lui, Grace Chung Yan
Wong, Candy Ngai Sze
Yip, Sindy Sin Ting
Li, Timothy Chun Man
Cheung, Catherine Siu King
Sze, Ryan Kin Ho
Szeto, Cheuk Chun
Chow, Kai Ming
CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) : 1406 - 1412
[3] Short-term Pregnancy Outcomes After Nirmatrelvir-Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Loza, Alexandra
Farias, Ryan
Gavin, Nicole
Wagner, Richard
Hammer, Erica
Shields, Andrea
OBSTETRICS AND GYNECOLOGY, 2022, 140 (03): : 447 - 449
[4] Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series
Breeden, Madison
Aitken, Samuel L.
Baang, Ji Hoon
Gravelin, Misty
Kaul, Daniel R.
Lauring, Adam S.
Petty, Lindsay A.
Gregg, Kevin S.
OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
[5] Treatment of persistent coronavirus disease 2019 (COVID-19) in a B cell acute lymphoblastic leukemia patient with using nirmatrelvir/ritonavir extended course: A case report
Almarhabi, Hassan
Alharbi, Aisha
Alalawi, Mai
Ahamed, Mohamed Firoze
El-Hemaidi, Ihab
Damfu, Nader
JOURNAL OF INFECTION AND PUBLIC HEALTH, 2024, 17 (10)
[6] A Multinational Case Series Describing Successful Treatment of Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Caused by Omicron Sublineages With Prolonged Courses of Nirmatrelvir/Ritonavir
Snell, Luke B.
McGreal-Bellone, Aimee
Nye, Clemency
Gage, Sarah
Bakrania, Prijay
Williams, Tom G. S.
Aarons, Emma
Botgros, Alina
Douthwaite, Samuel T.
Mallon, Patrick
Milligan, Iain
Moore, Catherine
O'Kelly, Brendan
Underwood, Jonathan
de Barra, Eoghan
Nebbia, Gaia
OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
[7] Comparison of safety and ef fi cacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study
Chu, Wing Ming
Wan, Eric Yuk Fai
Wong, Zoey Cho Ting
Tam, Anthony Raymond
Wong, Ian Chi Kei
Chan, Esther Wai Yin
Hung, Ivan Fan Ngai
ECLINICALMEDICINE, 2024, 72
[8] Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals
Smith-Jeffcoat, Sarah E.
Biddle, Jessica E.
Talbot, H. Keipp
Morrissey, Kerry Grace
Stockwell, Melissa S.
Maldonado, Yvonne
McLean, Huong Q.
Ellingson, Katherine D.
Bowman, Natalie M.
Asturias, Edwin
Mellis, Alexandra M.
Johnson, Sheroi
Kirking, Hannah L.
Rolfes, Melissa A. R.
Olivo, Vanessa
Merrill, Lori
Battan-Wraith, Steph
Sano, Ellen
McLaren, Son H.
Vargas, Celibell Y.
Goodman, Sara
Sarnquist, Clea C.
Govindaranjan, Prasanthi
Petrie, Joshua G.
Belongia, Edward A.
Ledezma, Karla
Pryor, Kathleen
Lutrick, Karen
Bullock, Ayla
Yang, Amy
Haehnel, Quenla
Rao, Suchitra
Zhu, Yuwei
Schmitz, Jonathan
Hart, Kimberly
Grijalva, Carlos G.
Salvatore, Phillip P.
CLINICAL INFECTIOUS DISEASES, 2023, : 1175 - 1184
[9] Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 (COVID-19) Lower Respiratory Tract Disease in a B-cell Acute Lymphoblastic Leukemia (ALL) Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir
Ford, Emily S.
Simmons, William
Karmarkar, Ellora N.
Yoke, Leah H.
Braimah, Ayodale B.
Orozco, Johnnie J.
Ghiuzeli, Cristina M.
Barnhill, Serena
Sack, Coralynn L.
Benditt, Joshua O.
Roychoudhury, Pavitra
Greninger, Alexander L.
Shapiro, Adrienne E.
Hammond, Jennifer L.
Rusnak, James M.
Dolsten, Mikael
Boeckh, Michael
Liu, Catherine
Cheng, Guang-Shing
Corey, Lawrence
CLINICAL INFECTIOUS DISEASES, 2023, 76 (05) : 926 - 929
[10] Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19)
Li, Hongyan
Gao, Menghan
You, Hailong
Zhang, Peng
Pan, Yuchen
Li, Nan
Qin, Ling
Wang, Heyuan
Li, Dan
Li, Yang
Qiao, Hongmei
Gu, Lina
Xu, Songbai
Guo, Weiying
Wang, Nanya
Liu, Chaoying
Gao, Pujun
Niu, Junqi
Cao, Jie
Zheng, Yang
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E148 - E154

← 1 →